Oligomer dynamics for drug discovery against α-synuclein aggregation in Parkinson's disease
View / Open Files
Authors
Staats, Roxine
Advisors
Vendruscolo, Michele
Date
2021-06-14Awarding Institution
University of Cambridge
Qualification
Doctor of Philosophy (PhD)
Type
Thesis
Metadata
Show full item recordCitation
Staats, R. (2021). Oligomer dynamics for drug discovery against α-synuclein aggregation in Parkinson's disease (Doctoral thesis). https://doi.org/10.17863/CAM.87805
Abstract
The aberrant aggregation of α-synuclein in Parkinson’s disease and related synucleinopathies is a histological hallmark of these conditions, as well as a cytotoxic process with no known disease-modifying interventions. While many studies have sought to develop small molecules or other biologics that may abrogate fibril formation, it is becoming increasingly clear that the toxicity
associated with α-synuclein aggregation may be linked to soluble oligomeric species that serve as precursors to mature fibrils. These intermediate species are transient, amorphous and highly heterogenous in solution, which has precluded the study of their population dynamics in the context of drug discovery and screening. This thesis will aim to leverage a combination of theoretical and experimental approaches to model the flux towards oligomeric species formation within the fibril amplification process of α-synuclein, and subsequently to employ this flux as a selection parameter in drug discovery. By using this approach, possible strategies will be investigated to reduce oligomeric species formation and show that a particularly effective approach is to design small molecules that bind to the autocatalytic fibril surface of α-synuclein in a structure-based approach. Overall, the thesis aims to demonstrate the viability of the prediction and targeting of oligomeric α-synuclein species during
secondary nucleation as a drug discovery pipeline that yields more robust links to the in vitro profile of an α-synuclein aggregation inhibitor and its resulting effect on α-synuclein-mediated toxicity in Parkinson’s disease pathology.
Keywords
Parkinson's disease, chemistry, drug discovery, biophysics, protein aggregation, neurodegeneration, Alzheimer's disease, oligomer
Embargo Lift Date
2023-08-23
Identifiers
This record's DOI: https://doi.org/10.17863/CAM.87805
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk